HCW Biologics Inc (nasdaq:HCWB) Share Price

Company Profile

Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USA
T: +1 954 842-2024
https://www.hcwbiologics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35

Recommended

Fear outweighs fundamentals as ASX share reaffirms outlook.

Nathan Zaia | 29 October 2026

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,099.20	86.60	0.96%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	22,958.65	136.18	-0.59%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	63,395.61	1,263.86	-1.95%
NZX 50 Index	13,726.96	16.79	0.12%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,982.80	91.00	1.02%
SSE Composite Index	3,651.41	0.03	-0.00%